CDKN2A and central nervous system cancer: Based on molecular classification indicators of gliomas in previous studies, we simplified these studies: IDHR132H21 (R132H mutation in IDH1) was used to detect IDH mutated proteins, ATRX, EGFR (Epidermal Growth Factor Receptor), and CDKN2A were used to reflect ATRX, EGFR, and CDKN2A mutations [12, 22, 23], respectively.